Grindeks invests 1.6 million lats in the Quality control laboratory
November 27, 2013
JSC „Grindeks" informs on its investment of 1.6 million lats in the Quality control laboratory, out of which 1.33 million lats will be invested in the construction, but more than 270 thousand lats – in the modern quality control equipment. The project is being carried out to increase the capacity of Microbiology laboratory, which is a unit of Quality control laboratory, and to adapt new pharmaceutical requirements.
The new laboratory will perform pharmaceutical analyses, development and validation of analytical methods. All activities in the laboratory will conform to principles of Good manufacturing Practice (GMP), ISO 9001 and ISO 14001.
By expanding opportunities of quality control „Grindeks" will provide analytical services for Latvia's and foreign companies and perform analyses of pharmaceutical products – final dosage forms (tablets, capsules, ointments, gels, syrups, solutions for injections), API's, as well as the analyses of technological experiments and cleaning validation. The company will perform batch release of pharmaceutical products for EU and CIS countries.
Dr.chem Juris Hmeļņickis, Quality director at JSC „Grindeks": „The quality requirements in the pharmaceutical industry and the area of Good Manufacturing Practice increase every year. Producing medications and recognizing our important mission of caring for people's health, „Grindeks" constantly improves the performance in quality field. This project will strengthen „Grindeks" positions and increase our competitiveness. In addition, it will open up opportunities to provide analytical services to other companies in Latvian and abroad."
Laboratory project is being implemented in several stages. The project is expected to be completed in May, 2014.
According to the project Microbiology laboratory area will be 250m², but the Quality control laboratory will have a total area of 700m ². The new laboratory will be installed in modern automatic control system that regulates the microclimate and engineering systems, as well as saving energy resources.
"Grindeks" is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. The Group of "Grindeks" consists of four subsidiary companies in Latvia, Estonia and Russia, as well as representative offices in 13 countries.
"Grindeks" specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. A range of products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics included therein. Currently "Grindeks" produces 24 active pharmaceutical ingredients.
Products of the company are exported to 55 countries and its export comprises more than 95% of the total turnover. The main markets are: Russia and other CIS countries, the Baltic States, Germany, the Netherlands, Japan and the U.S.
To increase production capacity and develop infrastructure, since 2002 the company has accomplished many significant investment projects, investing 45.6 million lats over the years.
JSC "Grindeks" shares are listed on the Official List of "NASDAQ OMX Riga". Major shareholders of JSC "Grindeks" are Kirovs Lipmans – 33.29%, Anna Lipmane – 16.69%, "AB.LV Private Equity fund 2010" – 11.38%, "Skandinaviska Enskilda Banken" (nominal holder) – 10.02%, "Swedbank" AS Clients Account (nominal holder) – 8.84%.
More information about the company – www.grindeks.lv/en/
Head of the Communications Department, JSC "Grindeks"
Phones: (+371) 67083370, (+371) 29256012
Fax: (+371) 67083505